Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases
Publication
, Journal Article
Schreiber, K; Giles, I; Costedoat-Chalumeau, N; Nelson-Piercy, C; Dolhain, RJ; Mosca, M; Förger, F; Fischer-Betz, R; Molto, A; Tincani, A ...
Published in: Lancet Rheumatology
September 1, 2023
Duke Scholars
Published In
Lancet Rheumatology
DOI
EISSN
2665-9913
Publication Date
September 1, 2023
Volume
5
Issue
9
Start / End Page
e501 / e506
Related Subject Headings
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Schreiber, K., Giles, I., Costedoat-Chalumeau, N., Nelson-Piercy, C., Dolhain, R. J., Mosca, M., … Andreoli, L. (2023). Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology, 5(9), e501–e506. https://doi.org/10.1016/S2665-9913(23)00215-1
Schreiber, K., I. Giles, N. Costedoat-Chalumeau, C. Nelson-Piercy, R. J. Dolhain, M. Mosca, F. Förger, et al. “Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases.” Lancet Rheumatology 5, no. 9 (September 1, 2023): e501–6. https://doi.org/10.1016/S2665-9913(23)00215-1.
Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, et al. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology. 2023 Sep 1;5(9):e501–6.
Schreiber, K., et al. “Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases.” Lancet Rheumatology, vol. 5, no. 9, Sept. 2023, pp. e501–06. Scopus, doi:10.1016/S2665-9913(23)00215-1.
Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, Förger F, Fischer-Betz R, Molto A, Tincani A, Pasquier E, Marin B, Elefant E, Salmon J, Bermas BL, Sammaritano L, Clowse MEB, Chambers C, Buyon J, Inoue SA, Agmon-Levin N, Aguilera S, Emadi SA, Andersen J, Andrade D, Antovic A, Arnaud L, Christiansen AA, Avcin T, Badreh-Wirström S, Bertsias G, Bini I, Bobirca A, Branch W, Brucato A, Bultink I, Capela S, Cecchi I, Cervera R, Chighizola C, Cobilinschi C, Cuadrado MJ, Dey D, Etomi O, Espinosa G, Flint J, Fonseca JE, Fritsch-Stork R, Gerosa M, Glintborg B, Skorpen CG, Goulden B, Graversgaard C, Gunnarsson I, Gupta L, Hetland M, Hodson K, Hunt BJ, Isenberg D, Jacobsen S, Khamashta M, Levy R, Linde L, Lykke J, Meissner Y, Moore L, Morand E, Navarra S, Opris-Belinski D, Østensen M, Ozawa H, Perez-Garcia LF, Petri M, Pons-Estel GJ, Radin M, Raio L, Rottenstreich A, Ruiz-Irastorza G, Tunjić SR, Rygg M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou M, Troldborg A, Vinet E, Vojinovic J, Voss A, Wallenius M, Andreoli L. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. Lancet Rheumatology. 2023 Sep 1;5(9):e501–e506.
Published In
Lancet Rheumatology
DOI
EISSN
2665-9913
Publication Date
September 1, 2023
Volume
5
Issue
9
Start / End Page
e501 / e506
Related Subject Headings
- 3202 Clinical sciences